Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia.
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
13 May 2021
13 May 2021
Historique:
received:
25
01
2021
accepted:
29
04
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.
Identifiants
pubmed: 33985565
doi: 10.1186/s40364-021-00291-y
pii: 10.1186/s40364-021-00291-y
pmc: PMC8117650
doi:
Types de publication
Letter
Langues
eng
Pagination
35Subventions
Organisme : Rosetrees Trust
ID : Rosetrees Trust
Organisme : The big C
ID : The big C
Organisme : Janssen Pharmaceuticals
ID : Janssen Pharmaceuticals
Organisme : AbbVie
ID : AbbVie
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : Wellcome Trust
Pays : United Kingdom
Références
Cancer Discov. 2014 Mar;4(3):362-75
pubmed: 24346116
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Blood. 1993 Jun 1;81(11):3091-6
pubmed: 7684624
Haematologica. 2019 Mar;104(3):e100-e103
pubmed: 30190344
Blood Rev. 2017 Sep;31(5):277-286
pubmed: 28318761
Cancer Res. 2019 May 1;79(9):2285-2297
pubmed: 30622116
Haematologica. 2021 Feb 01;106(2):589-592
pubmed: 32193250
Cancer Discov. 2018 Dec;8(12):1566-1581
pubmed: 30185627
Adv Hematol. 2012;2012:524308
pubmed: 21941553
Nature. 1998 Jul 9;394(6689):133
pubmed: 9687260